FOLH1 and prostate carcinoma: 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) was approved by the U.S. Food and Drug Administration as the first prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging drug for patients with prostate cancer.